Packer (21) has summarized that SGLT2-inhibitors could protect HF both from activating the Sirt1/PGC1α/FGF21 signaling transition and directly upregulating the expression of Sirt1, PGC1α, and FGF21. This evidence concerns the gene SLC5A2 and hydrops fetalis.